As a tangential point, it's interesting that researchers for the ebola vaccine weren't able to obtain the same kind of funding so it could go through trials, be developed and deployed, ready for use ahead of the major outbreak in West Africa a couple of years ago.   It's very interesting given the extremely high mortality rate (75% or so) of outbreaks of that disease over the past few decades.   One has to wonder at what drives priorities for the WHO and other health organizations.

Vis-à-vis the funding of the Strensiq drug, why didn't the Globe and Mail article address this angle?   

And - yes, Canada (the provinces) are being bamboozled in the global prescription drug purchasing market from everything I've seen and heard.   No wonder healthcare costs are escalating.   It doesn't work to have substantial moral hazard built into accountability (or "lack- of- accountability") structures, especially in an area as technical as prescription drugs and medical treatments.